Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP‐TEAD Protein‐Protein Interaction Inhibitors
Holger Sellner(Novartis (Switzerland)), Nicolas Soldermann(Novartis (Switzerland))
Cited by 23
Related Papers
Discovery of 4-((2 <i>S</i> ,4 <i>S</i> )-4-Ethoxy-1-((5-methoxy-7-methyl-1 <i>H</i> -indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases
|Journal of Medicinal Chemistry|2020|61